A couple of years ago, we started playing with the massive amounts of data that MarketBeat takes in everyday trying to figure out if there was a way to identify short term trading wins.
By analyzing earnings data, news sentiment, analyst recommendations, insider transactions and dozens of other data points, we think we’ve found an algorithm that finds interesting short-term stock ideas.
We call that algorithm the IdeaEngine and its stock ideas are published on MarketBeat All Access every Monday morning.
We make one IdeaEngine idea available free every Monday as an SMS alert. We’ll be releasing the next IdeaEngine alert on Monday morning, so make sure you are signed up before then.
Get MarketBeat’s Free Weekly IdeaEngine Stock Picks Here
William Bushee
MarketBeat
P.S. The IdeaEngine has had some good stock ideas recently, but it’s just an algorithm. It’s not always right and it should be only part of your research process. Remember that stock investing and trading involves risk and you should always consult with a competent financial professional before making investment decisions. Read our full terms of service here.
REalloys Could Be the Missing Link in America's Rare Earth Defense Gap
Reported by Bridget Bennett. Article Posted: 3/3/2026.
Key Points
- REalloys argues the true rare-earth chokepoint for defense is heavy rare-earths—especially refining and rare-earth metallization, not just mining.
- A 2027 deadline could force defense contractors to certify supply chains that exclude certain foreign sources, increasing urgency for North American capacity.
- Early steps include a Canada processing offtake, an Ohio metallization facility, and a new Defense Logistics Agency contract tied to process and facility design.
- Special Report: [Sponsorship-Ad-6-Format3]
The latest round of geopolitical tension has defense stocks bouncing higher. But the rally isn't limited to weapons makers—it's also drawing fresh attention to the critical rare-earth materials that those defense systems can't function without.
In a recent MarketBeat conversation, Tim Johnston of REalloys Inc. (NASDAQ: ALOY) laid out why the company believes the next chapter for rare-earths in North America won't be defined by who finds the minerals in the ground, but by who can actually refine, metallize, and deliver them to the defense contractors that need them now.
Using the same system that helped me spot Nvidia at $1, I've just issued my #1 AI pick for 2026 (Ad)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.
Get the name and ticker of Louis Navellier's #1 AI stock freeREalloys recently traded in the high-teens range after debuting on the NASDAQ in late February through a reverse merger with Blackboxstocks. The stock experienced significant volatility in its first days of trading, reaching a high near $19.75 before pulling back.
Why Heavy Rare-Earths Are the Real Defense Bottleneck
Most investors hear "rare-earths" and think of a single commodity. The reality is more nuanced. Rare-earth elements split into two categories—lights and heavies—and the distinction matters enormously for defense.
Light rare-earths go into everyday permanent magnets for home appliances and standard electric vehicles. Heavy rare-earths are the high-performance enablers: the materials that allow magnets to function in extreme temperatures inside fighter jets, submarines, drones, and advanced robotics.
"Without these components, you simply can't make those instruments perform the way you want them to perform," Johnston said, pointing to high-performance magnets as the linchpin. "Particularly when we're talking about drones and robotics—they're critically important to actually making those things work in the first place."
China's Grip: The Supply Chain Vulnerability Driving U.S. Investment
The geopolitical math is straightforward. China currently controls roughly 90% of all rare-earth refining and, until very recently, handled 100% of global heavy rare-earth metallization. About 70% of raw mining also originates from Chinese sources.
Johnston framed the risk in blunt terms: "You take that away, China shuts down supply, and then all of a sudden you can't build those things that you need for defense technology and really important infrastructure."
That vulnerability is why the U.S. government has announced tens of billions of dollars in investment across programs designed to build a North American allied supply chain. In Johnston's telling, the industry is roughly 30 years behind China—and the catch-up is happening across mining, refining, separation, and magnet manufacturing simultaneously.
How REalloys Is Assembling Its Supply Chain—Without Starting From Scratch
Asked what sets REalloys apart from the growing field of rare-earth developers, Johnston pointed to speed-to-market. Rather than pursuing a years-long greenfield mining buildout, the company has assembled existing assets and partnerships designed to deliver product quickly.
The first piece is a five-year offtake agreement with the Saskatchewan Research Council, which operates a commercial-scale rare-earth processing facility in Saskatoon, Canada. For the first five years, feedstock will come from Brazil, South Africa, and North American sources, all refined in Canada.
The second piece is the acquisition of PMT Critical Metals in Euclid, Ohio—a 54,000-square-foot facility with more than two decades of experience producing specialty metals for the Defense Logistics Agency, the Department of Energy, the Department of Defense, and NASA. This is where the final metallization step and eventual magnet production will happen.
Johnston described the ability to be "coming to the market with product by the end of this year" as a "huge milestone" and a key differentiator from peers still years away from production.
The 2027 Deadline: A Regulatory Catalyst With Real Teeth
The timeline matters because of a hard legislative requirement under 10 U.S.C. §4872. Starting Jan. 1, 2027, defense contractors must certify that their entire rare-earth supply chain—from mining through metallization—is free of materials sourced from China, Russia, Iran, or North Korea.
Johnston put it directly: short of a presidential authorization waiver, REalloys will be "the primary producer of heavy rare-earth in North America" capable of meeting that standard. That's management commentary rather than an independently confirmed assessment, but the competitive landscape for heavy rare-earth metallization outside China is genuinely thin.
A Concrete Win: New DLA Contract for Samarium and Gadolinium
One of the most actionable developments this week centered on a new DLA contract awarded to REalloys' subsidiary Terves LLC, worth up to $1.7 million. The contract funds the engineering design for a 300-ton-per-year modular production facility for samarium and gadolinium—two heavy rare-earth metals critical to defense magnet applications.
The structure matters. This isn't a simple metals delivery agreement; it's a process-development and facility-design contract that could lay the groundwork for significantly larger production commitments. REalloys also filed a provisional patent covering a zero-waste metallization process it claims could cut production costs by up to 50%.
The Board Signals Defense Credibility
REalloys has assembled a board designed to project seriousness in defense circles. Stephen duMont, President of GM Defense, serves as non-executive chairman. Retired four-star General Jack Keane—a longtime adviser to multiple presidential administrations who received the Presidential Medal of Freedom in 2020—joined as a director ahead of the NASDAQ listing.
The Investor Question: Can REalloys Execute Before the Clock Runs Out?
REalloys is a reminder of how quickly a policy catalyst can reshape a sector—especially when national security urgency collides with a supply chain that barely exists outside of one country.
But Johnston's argument was that the window is just opening. "This is a massively growing sector," he said. "The demand for these materials is growing exponentially, particularly when you factor in the need to diversify away from a Chinese-dominated industry."
Whether that plays out cleanly will depend on execution—meeting the end-of-year production target, scaling the Ohio and Saskatchewan operations, and converting engineering contracts into full-scale supply agreements.
Still, the combination of a hard regulatory deadline, genuine scarcity outside China, and early contract wins with defense agencies helps explain why this newly public company is drawing attention in a crowded rare-earth field. The risk is that timelines slip. The upside is that very few companies are even close to delivering what the U.S. defense sector will legally require in less than a year.
3 Undervalued Names Too Cheap to Ignore
Reported by Nathan Reiff. Article Posted: 3/7/2026.
Key Points
- Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
- Special Report: [Sponsorship-Ad-6-Format3]
Highly publicized growth trajectories of some of the biggest companies out there may make it seem like 2026 is not a prime time for a value strategy. Still, several sizable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth.
The companies below all represent potential value plays, with metrics that are historically low and/or competitive relative to peers or the broader market. They also offer added benefits, including compelling dividends or promising product developments. While value opportunities can be harder to find when many companies have already regained investor attention (and some apparent bargains have deteriorating operations or other red flags), well-established and stable names can still present value prospects.
Even After a Rally, Merck May Still Be Undervalued as It Plans for Keytruda's Patent Loss
Using the same system that helped me spot Nvidia at $1, I've just issued my #1 AI pick for 2026 (Ad)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.
Get the name and ticker of Louis Navellier's #1 AI stock freeAlthough shares have climbed more than 28% in the last year, bringing biopharma giant Merck & Co. Inc. (NYSE: MRK) to a market capitalization near $300 billion, its price-to-earnings (P/E) ratio is 16.45—well below the medical industry average of roughly 27. Analysts expect continued growth: Merck is projected to see earnings rise by nearly 10% in the coming year and has a 5% additional upside in the near term.
Driving Merck's momentum is its pembrolizumab cancer drug, Keytruda, which received European Commission approval for subcutaneous injection in late 2025 and reached about $8.4 billion in sales in Q4 2025, an increase of nearly 7% year over year. Keytruda also shows promise for ovarian cancer indications, potentially expanding its patient base. These dynamics should help Merck build revenue as it prepares for Keytruda's patent expiration in 2028.
Merck's broader drug portfolio is also expanding: the company recently announced phase 3 trial results for clesrovimab-cfor (Enflonsia), an RSV treatment for young children. At the same time, Merck is reorganizing its human health operations into two units to make it easier to grow non–cancer drug sales as Keytruda approaches patent loss.
External Pressures Have Weighed on Campbell's, but Dividend and Valuation Appeal Remain
Campbell's (NASDAQ: CPB) shares have fallen about 37% over the last year as the food-and-beverage staple faced tariff and inflationary pressures. In Q1 fiscal 2026 (ended Nov. 2, 2025), the company reported modest year-over-year declines in organic net sales and consumption, and adjusted earnings per share (EPS) dropped by 13% over the same period. The company has not yet realized notable margin improvement following cost-saving initiatives.
The near term is likely to remain challenging for the iconic brand given weak fiscal-year guidance.
However, improving supply-chain execution and strong brand loyalty—especially for premium offerings—should help protect market share. Evolving tariff dynamics may also ease some of the pressures the company faces.
Additionally, Campbell's remains an attractive dividend play, offering an impressive yield of 5.9%, though its payout ratio is fairly high at over 80%. Its P/E ratio of 13.5 is the lowest in about four years, factors that may persuade some investors that the stock is worth the risk despite Wall Street caution.
US Foods' Recent Rally May Continue as Bottom-Line Growth Persists
Foodservice distribution leader US Foods (NYSE: USFD) has seen a nearly opposite trajectory to Campbell's—shares climbed about 33% over the last year. Its P/E ratio sits at 31.6.
On fundamentals, US Foods is making meaningful progress: the company reported improving profitability in the latest quarter and achieved full-year adjusted EBITDA gains of 11% year over year. Better inventory management and cost-of-goods improvements are helping the firm gain traction. With a $4 billion capital deployment strategy in place, US Foods is positioned to maintain revenue momentum and continue growing adjusted EBITDA.
Analysts rate USFD a Moderate Buy based on 11 Buys and 2 Holds, with roughly 15% upside potential.
We empower investors to make better financial decisions by offering real-time financial information and objective market research.
This email message is a sponsored message provided by MarketBeat Alerts, a third-party advertiser of MarketBeat. Why did I receive this message?.
If you need help with your newsletter, please contact our U.S. based support team at contact@marketbeat.com.
If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails.
© 2006-2026 MarketBeat Media, LLC. All rights protected.
345 N Reid Place #620, Sioux Falls, South Dakota 57103. United States of America..